Program
bremelanotide
Also written as “Bremelanotide” and “Vyleesi (Bremelanotide Injection)”.
Its studies are mostly in Sexual Dysfunctions, Psychological · Obesity · Kidney Diseases, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Palatin Technologies | 61 open or running | phase 3since Dec 28, 2014 | Jan 18, 2007 | none ahead |
| Cosette Pharmaceuticals | 10 open or running | phase 4since Feb 19, 2025 | Feb 19, 2025 | none ahead |
| Kwang Dong Pharmaceutical | 10 open or running | phase 3since Jun 10, 2021 | Jun 10, 2021 | none ahead |
Also a collaborator on its studies: Azurity Pharmaceuticals and king-pharmaceuticals-is-now-a-wholly-owned-subsidiary-of-pfi.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 18, 2007First study: phase 2 study in Sexual Dysfunctions, PsychologicalNew to Palatin TechnologiesPalatin Technologies · NCT00425256 · United States
- Jun 24, 2011Phase 2 study in Sexual Dysfunctions, PsychologicalPalatin Technologies · NCT01382719 · 612 enrolled · United States, Canada
- Dec 28, 2014Phase 3 study in Sexual Dysfunctions, PsychologicalPalatin Technologies · NCT02333071 · 723 enrolled · United States, Canada
- Jan 12, 2015Phase 3 study in Sexual Dysfunctions, PsychologicalPalatin Technologies · NCT02338960 · 714 enrolled · United States, Canada
- Jun 10, 2021Kwang Dong Pharmaceutical's first study: phase 3 study in Sexual Dysfunctions, PsychologicalNew to Kwang Dong PharmaceuticalKwang Dong Pharmaceutical · NCT04943068 · 193 enrolled · Korea, Republic of
- Jan 6, 2023Phase 2 study in Kidney DiseasesPalatin Technologies · NCT05709444 · 16 enrolled · United States
- Jun 5, 2024Phase 2 study in ObesityPalatin Technologies · NCT06565611 · 108 enrolled · United States
- Feb 19, 2025Cosette Pharmaceuticals's first study: phase 4 study in Lactating MotherNew to Cosette PharmaceuticalsCosette Pharmaceuticals · NCT06867835 · 10 enrolled · United States
TargetBeta
“Melanocortin receptor 4 agonist; Melanocortin receptor 4 agonist”ChEMBL 37, by rule
Other programs on MC4R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| setmelanotiderule | Rhythm Pharmaceuticals | phase 4 | 22 |
| bivamelagonrule | Rhythm Pharmaceuticals | phase 2 | 3 |
| mifomelatiderule | endevica-bio | phase 2 | 2 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06867835Lactating Mother · United States | 4 | Completed | Cosette Pharmaceuticals | Nov 15, 2025 | 10 |
| NCT06565611Obesity · United States | 2 | Active, not recruiting | Palatin Technologies | Feb 5, 2025 | 108 |
| NCT05709444Kidney Diseases · United States | 2 | Completed | Palatin Technologies | Apr 26, 2024 | 16 |
| NCT04943068Sexual Dysfunctions, Psychological · Korea, Republic of | 3 | Completed | Kwang Dong Pharmaceutical | May 16, 2023 | 193 |
| NCT02338960Sexual Dysfunctions, Psychological · United States, Canada | 3 | Completed | Palatin Technologies | Aug 2016 | 714 |
| NCT02333071Sexual Dysfunctions, Psychological · United States, Canada | 3 | Completed | Palatin Technologies | Jul 2016 | 723 |
| NCT01382719Sexual Dysfunctions, Psychological · United States, Canada | 2 | Completed | Palatin Technologies | Sep 2012 | 612 |
| NCT00425256Sexual Dysfunctions, Psychological · United States | 2 | Completed | Palatin Technologies | May 2007 |
How it is read
Names in the registry
- “Bremelanotide”, 5 entries
- “bremelanotide”, 2 entries
- “Vyleesi (Bremelanotide Injection)”, 1 entry
Conditions, from the studies’ own filings
- Sexual Dysfunctions, Psychological, 5 studies
- Obesity, 1 study
- Kidney Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.